St. James s Hospital ( Site 1601)(3.9 mi away)Contact
+146 other location
This is a randomized, double-blind, study that compares pembrolizumab with placebo given as
adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell
carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with
radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in
increasing recurrence free survival (RFS).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.